Intech Investment Management LLC Grows Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Intech Investment Management LLC lifted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 40.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 28,248 shares of the biopharmaceutical company's stock after purchasing an additional 8,170 shares during the period. Intech Investment Management LLC's holdings in Agios Pharmaceuticals were worth $928,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $33,000. Wingate Wealth Advisors Inc. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $53,000. KBC Group NV increased its stake in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 611 shares during the period. Quest Partners LLC raised its holdings in Agios Pharmaceuticals by 139.6% during the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company's stock valued at $98,000 after buying an additional 1,283 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Agios Pharmaceuticals in the 3rd quarter worth $146,000.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. StockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada lifted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. Finally, Scotiabank increased their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, December 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $56.57.

Remove Ads

Insider Activity

In related news, insider Tsveta Milanova sold 2,804 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Trading Up 1.4 %

AGIO traded up $0.44 during midday trading on Thursday, reaching $30.84. The company's stock had a trading volume of 460,811 shares, compared to its average volume of 680,920. Agios Pharmaceuticals, Inc. has a 1 year low of $27.14 and a 1 year high of $62.58. The stock's 50-day moving average is $33.23 and its 200-day moving average is $41.04. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of 2.72 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.